Teva Pharmaceuticals engages Honeywell to help reduce carbon impact
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Subscribe To Our Newsletter & Stay Updated